John Gill
CIK 1409939 · President and CEO · last filed 2026-05-01
John Gill is a President and CEO who has filed 28 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for ALT, was dated May 1, 2026. Across all open-market trades the lifetime net is −$54.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $48.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG, MD 20878
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALT | Director | 21,700 | $2.23 | $48.4K | -$54.2K | 16 | 2026-05-01 |
| Altimmune, Inc. (PIP) Delisted | President and CEO | 82,224 | — | — | $0 | 12 | 2016-11-23 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-01 | ALT | Grant (A) | — | $0 | EDGAR |
| 2026-04-06 | ALT | Buy (P) | +9,200 | $31.3K | EDGAR |
| 2025-12-23 | ALT | Buy (P) | +12,500 | $51.2K | EDGAR |
| 2025-09-29 | ALT | Mixed | −2,714 | $0 | EDGAR |
| 2024-09-30 | ALT | Grant (A) | — | $0 | EDGAR |
| 2023-09-29 | ALT | Grant (A) | — | $0 | EDGAR |
| 2023-07-06 | ALT | Sell (S) | −2,714 | -$40.7K | EDGAR |
| 2022-09-30 | ALT | Grant (A) | — | $0 | EDGAR |
| 2021-09-24 | ALT | Grant (A) | — | $0 | EDGAR |
| 2020-12-02 | ALT | Sell (S) | −8,425 | -$100.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.